Alpha Tau Medical (NASDAQ:DRTS) CFO Sells 17,500 Shares of Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 17,500 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $9.55, for a total transaction of $167,125.00. Following the transaction, the chief financial officer owned 130,180 shares in the company, valued at $1,243,219. The trade was a 11.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.

Alpha Tau Medical Stock Up 7.3%

DRTS traded up $0.74 during midday trading on Thursday, hitting $10.79. The company had a trading volume of 244,277 shares, compared to its average volume of 550,900. The stock’s 50 day moving average price is $9.27 and its 200 day moving average price is $7.54. Alpha Tau Medical Ltd. has a 52 week low of $2.87 and a 52 week high of $11.62. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $974.30 million, a price-to-earnings ratio of -16.19 and a beta of 1.19.

Alpha Tau Medical (NASDAQ:DRTS) last announced its quarterly earnings data on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). On average, research analysts anticipate that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alpha Tau Medical

Institutional investors have recently bought and sold shares of the stock. Trifecta Capital Advisors LLC bought a new position in Alpha Tau Medical during the 4th quarter valued at $48,000. Envestnet Asset Management Inc. bought a new stake in shares of Alpha Tau Medical in the 3rd quarter worth $62,000. Bank of America Corp DE grew its stake in shares of Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock worth $101,000 after acquiring an additional 21,677 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in shares of Alpha Tau Medical in the first quarter valued at about $132,000. Institutional investors own 2.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DRTS. Barclays lifted their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. Citigroup upped their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Piper Sandler raised their price objective on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research note on Tuesday, May 19th. LADENBURG THALM/SH SH lifted their price objective on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $12.60.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.